It's a subdued start to trading with tariff talk dampening US markets. Pharmaceutical and Energy stocks are the unlucky ...

SGX301 has shown rapid and sustained benefit in early cutaneous T-cell lymphoma in an investigator-initiated study, with good ...

Soligenix, Inc. (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, ...

Interim Results from FDA-Funded Study Reinforces HyBryte's Rapid Response and Strong Safety Profile PRINCETON, N.J., April 14, 2025 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix ...

Following a successful Type B end-of-phase 2 meeting, the FDA has approved the start of a phase 3 trial of linperlisib in peripheral T-cell lymphoma. The FDA has granted clearance to initiate a global ...

Shuai Chen, MD https://orcid.org/0009-0007-8628-4313 Department of Neurology, The People’s Hospital of Zhengzhou University and Henan Provincial People’s Hospital ...

Mangione's lawyer, Karen Friedman Agnifilo, has argued that Mangione can't mount a defense if he has to store all of the 15,000 pages of disclosed prosecution evidence in his New York prison cell.

The US Food and Drug Administration (FDA) approved the first CAR T-cell therapies in 2017 for diffuse large B-cell lymphoma and acute lymphoblastic leukemia in pediatric and young adult patients.

These findings were suggestive of T-cell lymphoma. Serologies for tuberculosis ... We diagnosed folliculotropic mycosis fungoides with early large-cell transformation (stage IIIB). We referred the ...